A consecutive series of 30 malignant schwannomas. Survival in relation to clinico-pathological parameters and treatment.

M. Bojsen-Møller, O. Myhre-Jensen
{"title":"A consecutive series of 30 malignant schwannomas. Survival in relation to clinico-pathological parameters and treatment.","authors":"M. Bojsen-Møller, O. Myhre-Jensen","doi":"10.1111/J.1699-0463.1984.TB04389.X","DOIUrl":null,"url":null,"abstract":"Thirty malignant schwannomas from an 18-year period were studied, and the patients were divided into 3 groups: one with Recklinghausen's disease, one with tumours related to nerves but without Recklinghausen's disease and finally one with a histopathology best compatible with malignant schwannoma. On all tumours a histopathological grading was performed, and all except two were found to be high-grade malignant. The follow-up is from 2 to 20 years, and only two of the living patients have not yet been followed for 5 years. One patient has been lost during the follow-up period. In the remaining 27 patients the 5-year survival is 48%. The factors essential to the prognosis are: the tumour localization, size, grade of malignancy and radical surgical treatment. The coexistence of Recklinghausen's disease and malignant schwannoma seems not in itself to give a worse prognosis; it is rather the large tumours and unfavourable localizations in this group of patients that shortens the survival, the 5-year survival being 37.5%.","PeriodicalId":77652,"journal":{"name":"Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology","volume":"20 1","pages":"147-55"},"PeriodicalIF":0.0000,"publicationDate":"2009-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"28","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/J.1699-0463.1984.TB04389.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 28

Abstract

Thirty malignant schwannomas from an 18-year period were studied, and the patients were divided into 3 groups: one with Recklinghausen's disease, one with tumours related to nerves but without Recklinghausen's disease and finally one with a histopathology best compatible with malignant schwannoma. On all tumours a histopathological grading was performed, and all except two were found to be high-grade malignant. The follow-up is from 2 to 20 years, and only two of the living patients have not yet been followed for 5 years. One patient has been lost during the follow-up period. In the remaining 27 patients the 5-year survival is 48%. The factors essential to the prognosis are: the tumour localization, size, grade of malignancy and radical surgical treatment. The coexistence of Recklinghausen's disease and malignant schwannoma seems not in itself to give a worse prognosis; it is rather the large tumours and unfavourable localizations in this group of patients that shortens the survival, the 5-year survival being 37.5%.
连续30例恶性神经鞘瘤。生存与临床病理参数和治疗的关系。
本文对30例恶性神经鞘瘤患者进行了18年的研究,将患者分为3组:一组为reclinghausen病,一组为与神经相关但无reclinghausen病的肿瘤,最后一组为与恶性神经鞘瘤最相容的组织病理学。对所有肿瘤进行组织病理学分级,除2例外均为高度恶性肿瘤。随访时间为2 ~ 20年,在世患者中仅有2例未随访5年。随访期间丢失1例患者。其余27例患者的5年生存率为48%。影响预后的关键因素是:肿瘤的定位、大小、恶性程度和根治性手术治疗。雷克林豪森氏病和恶性神经鞘瘤的共存本身似乎并不会带来更差的预后;在这组患者中,较大的肿瘤和不利的定位缩短了生存期,5年生存率为37.5%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信